CYP3A4: IHC Expression in Cancer and Radioligand Target Profile
CYP3A4, cytochrome P450 family 3 subfamily A member 4, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, CYP3A4 staining is highest in liver cancer (70% of samples positive) and pancreatic cancer (9% of samples positive). Clinical status: FDA-approved drug (any modality).
Is CYP3A4 the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.
Analyze CYP3A4 freeIs CYP3A4 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ⚠️ Tumor expression: Medium IHC staining in liver cancer, 70% of samples positive.
- ❔ Internalization: Not yet assessed.
- ✅ Clinical precedent: FDA-approved drug (any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
CYP3A4 IHC staining by cancer type
Protein expression of CYP3A4 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Liver Cancer | 0.50 | Medium | 70% |
| Pancreatic Cancer | 0.06 | Low | 9% |
Not detected by IHC in: skin cancer, colorectal cancer, head and neck cancer, ovarian cancer, lymphoma, breast cancer, melanoma, kidney cancer, thyroid cancer, bladder cancer, neuroendocrine tumors, cervical cancer, lung cancer, prostate cancer, gastric cancer, testicular cancer, endometrial cancer, glioma.
Is CYP3A4 internalized?
Nuclens has not yet extracted internalization evidence for CYP3A4. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a free analysis to pull the latest literature.
CYP3A4 clinical trials
FDA-approved drug (any modality). Nuclens hasn't indexed trials for CYP3A4 yet. Search ClinicalTrials.gov for CYP3A4 trials.
CYP3A4 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See CYP3A4 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
CYP3A4 gene essentiality (DepMap)
CRISPR knockout effect across 1247 cancer cell lines: 0.06 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related liver cancer radioligand targets
EGFR · c-MET (MET) · HER3 (ERBB3) · SSTR2 · STEAP2 · HER2 (ERBB2) · Mesothelin (MSLN) · B7-H3 (CD276)
See all radioligand therapy targets in liver cancer.
See how CYP3A4 ranks against 15,000 targets for your indication.
Analyze CYP3A4 freeData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.